Biosimilars Canada has compiled a list of news stories from Canada and abroad about biosimilars that may be of interest to readers. These links to third-party websites are provided for informational purposes only, and do represent an endorsement from our organization. Biosimilars Canada’s statements and news releases are available here.
New study from the Ontario Drug Policy Research Network (ODPRN) that estimates the number of patients potentially impacted by different biosimilar policy options in Ontario and the cost implications of these policies. Published in CMAJ Open.
The Pharmacy Consulting Team at Telus Health looks at how public drug plans are helping to drive the adoption of biosimilars in Canada. Third in series.
The Government of Ontario spending $3 million more than it needs to on biologic drugs every single week. Biosimilars are the solution, writes Biosimilars Canada President Jim Keon in his op-ed for QP Briefing.
This report from Canadian Institute for Health Information (CIHI) found that the uptake of biosimilars continued to increase in 2020, but reference biologic drugs continued to account for the majority of drug spending. When biosimilars were available for the reference biologic products, they accounted for 28.5% of biologic spending in 2020, up from 16.1% in 2019.
An overview of some of the latest key developments for biosimilars in Canada, including approvals, pending submissions and litigation, prepared by law firm Smart & Biggar.
Effective October 1, 2021, adult patients who take NovoRapid insulin aspart will be required to switch to a biosimilar version by April 1, 2022. All new patient starts for insulin aspart will be covered for a biosimilar.